Archan Ruparel

Archan Ruparel | Economist Expert Life Sciences | Charles River Associates

Mr. Ruparel advises clients on the economics of the life sciences industry. He has served as an expert witness and non-testifying expert on issues including antitrust liability, class certification, and damages.

Archan regularly provides economic expertise in disputes, including antitrust matters, intellectual property litigation, and commercial disputes. He has advised pharmaceutical companies, pharmacy benefits managers, insurers, and regulators. He has presented before federal and state regulators and provided analysis in disputes before regulatory boards, judges, arbitration panels, and juries. Mr. Ruparel has also assisted life sciences companies and counsel on complex questions involving development, pricing and market access, loss of exclusivity, and follow-on products.

Prior to joining CRA, Mr. Ruparel served in the Bureau of Economics of the Federal Trade Commission. At the FTC, Mr. Ruparel conducted a study of credit-based insurance scores and pharmaceutical direct-to-consumer advertising as well as investigations and litigation involving hospital mergers, telemarketing, and fair lending.

Mr. Ruparel serves on CRA’s pro bono committee.

Selected Engagements

  • 01
    ANDA challenge - Shire, Sanofi-Aventis, and Firazyr
    Shire, Sanofi-Aventis and Firazyr CRA consultants advised counsel to Shire Orphan Therapies, LLC (Shire) and Sanofi-Aventis Deutschland GMBH (Sanofi-Aventis)...
    View engagement
  • 02
    GlaxoSmithKline/Novartis/Eli Lilly Merger
    CRA economists advised Linklaters and Freshfields Bruckhaus Deringer, counsel to Novartis, throughout a three-part, $23 billion merger with GSK. Led by...
    View engagement
  • 03
    Assessment of global supply and demand in diagnostics arbitration
    CRA provided expert reports and hearing testimony on behalf of the respondent in an arbitration arising from an alleged breach of a supply agreement related to...
    View engagement